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ment for other factors. The R 2 of the model was 25.3%, indicat-Comorbidity assessment using the Index of Coexistent Dis-
ing that a substantial proportion of the variation in the ICEDeases in a multicenter clinical trial.
was not explained by these factors.Background. The Hemodialysis (HEMO) Study is a multi-
Conclusions. We conclude that comorbidity assessment us-center trial designed to determine whether hemodialysis dose
ing the ICED is feasible in multicenter clinical trials of dialysisand membrane flux affect survival. Comorbid conditions are
patients. There is a large burden of comorbidity in dialysis pa-also important determinants of survival, and thus, an accurate
tients, which is not well explained by the cause of renal disease,and reliable method to assess comorbidity was required. Co-
demographic, and socioeconomic factors and common clinicalmorbidity was being assessed at baseline and annually in the
and laboratory measurements. These variables should not be con-HEMO Study using the Index of Coexistent Disease (ICED).
sidered substitutes for comorbid conditions in case-mix adjust-We describe the instrument, its implementation in the HEMO
ment. Comorbidity assessment is useful to describe the sampleStudy, and the results of comorbidity assessment in the first
population, to improve the precision of the treatment effect,1000 randomized patients in the trial.
and to use possibly as an outcome measurement.Methods. The ICED aggregated the presence and severity of
19 medical conditions and 11 physical impairments within two
scales: the Index of Disease Severity (IDS) and the Index of
Physical Impairment (IPI). The final ICED score was deter-
Comorbid medical conditions are frequently seen inmined by an algorithm combining the peak scores for the IDS
dialysis patients and have an important effect on clinicaland IPI. The range of the ICED was from 0 to 3, reflecting
increasing severity. outcomes, including death, hospitalization, and quality of
Results. Study personnel at 15 clinical centers were trained life. The description of comorbidity in past studies has
to update and abstract data from the dialysis medical records. been highly variable [1–14], and even in those studies that
Availability of data, measures of construct validity, and mea-
employed a more structured assessment of comorbiditysures of reliability were adequate; 99.8% and 60.6% of patients
[1, 9, 14], there was little or no consideration of diseasehad comorbid conditions in at least one IDS or IPI category,
severity or physical limitations. Furthermore, disease defi-respectively. The distribution of patients by ICED level was 0
(0.2%), 1 (34.9%), 2 (31.2%), and 3 (33.7%). In multivariable nitions and the weights assigned to the individual comor-
analysis, the following factors were significantly associated with bid variables varied among studies, the latter dependent
more severe comorbidity: older age, diabetes and other causes
on the other comorbidity and case-mix factors that wereof renal disease, a lower level of education, employment status
adjusted for in the regression models. At present, there(unemployed and retired), longer duration of dialysis, and
is no agreement on a standardized method to measurelower serum creatinine. There was a significant variation in
the severity of comorbidity among clinical centers after adjust- and quantify the prognostic significance of comorbid
conditions in dialysis patients.
The Hemodialysis (HEMO) Study is an ongoing mul-1 A full listing of the members of the Hemodialysis Study investigators
ticenter (15 centers), randomized clinical trial sponsoredcan be found in The HEMO Study Group, prepared by Greene T, Beck
GJ, Gassman JJ, et al: Design and statistical issues of the Hemodialysis by the National Institute of Diabetes, Digestive and Kid-
(HEMO) Study. Control Clin Trials 21:502–525, 2000. ney Diseases (NIDDK) to assess the effect of hemodialy-
sis dose and membrane flux on mortality and hospitaliza-Key words: case-mix adjustment, risk assessment, randomized clinical
trial, population sampling, dialysis, instrument. tions in patients undergoing maintenance dialysis [15].
Comorbidity assessment in the HEMO Study is impor-Received for publication August 30, 2000
tant for three reasons. First, a description of comorbidand in revised form March 15, 2001
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of interest: prevalent hemodialysis patients with minimal primary disease itself. In the HEMO Study, comorbidity
residual renal function. Second, adjusting for the rela- is defined as all medical problems other than the cause of
tionship between comorbid conditions at baseline and renal disease. According to this definition, demographic
survival will assure comparability of randomized groups variables (such as age, gender, and race), socioeconomic
and permit a more precise estimate of the effect of the variables (such as level of education, income, and insur-
interventions; this study used a higher than usual hemo- ance), and clinical variables (such as blood pressure,
dialysis dose (as assessed by Kt/V for urea) and mem- dietary intake, laboratory tests, and anthropometry) are
brane flux (as assessed by clearance of 2-microglobulin) not comorbid conditions, although they may be associ-
[15, 16]. Third, an increase in the number and severity of ated with comorbidity.
comorbid conditions during follow-up may precede mor-
Assessment of comorbiditytality and, therefore, may be a useful surrogate outcome.
The Index of Coexistent Diseases (ICED) was used The ICED is based on the instrument originally de-
to assess comorbidity in the HEMO Study at baseline signed by Greenfield and colleagues for the purpose of
and yearly during follow-up. Two prior studies [11, 17] providing case-mix adjustment in the Medical Outcomes
and a preliminary report from an ongoing study (ab- Study [5, 21–24]. Since then, the ICED has been used
stract; Miskulin, J Am Soc Nephrol 10:175A, 1999) have in different settings, from serving as a predictor of long-
shown that the ICED is a strong, independent predictor term complications and functional impairments in post-
of death in dialysis patients. The risk of death was graded operative hip surgery patients [25] to controlling for se-
according to the incremental levels of the ICED, and verity of illness in comparing mortality rates in prostate
the results were consistent, independent of the size or cancer patients with an age-matched population [26]. Sub-
setting (that is, multicenter vs. single center) of these stud- sequently, the instrument was modified for use in dialysis
ies. The relationship between the baseline ICED level patients and found to be an independent predictor of
and death remained significant after adjustment for age, mortality and hospitalization [11, 17]. Further modifica-
serum albumin, diabetic status, and the number of co- tions to the ICED were made for the pilot phase of the
morbid conditions. To our knowledge, the HEMO Study HEMO Study.
is the first large multicenter clinical trial of dialysis pa- Additional items to define disease categories and sever-
tients to employ a prospective comprehensive assessment ity levels were developed, based on interviews with a panel
of comorbidity. This report describes the features of the of nephrologists (NVA, KBM, and ASL) and an exten-
ICED, its implementation in the HEMO Study, mea- sive review of 200 dialysis patients’ medical records. Se-
sures of data availability, construct validity and reliabil- verity levels were defined using examples of common
ity, and the baseline assessment of comorbidity of the
conditions encountered in dialysis patients. The categoryfirst 1000 patients enrolled in the trial.
for cardiovascular disease was expanded to four catego-
ries (ischemic heart disease, congestive heart failure, ar-
METHODS rhythmia, and other heart disease). We reasoned that
the additional categories would facilitate a detailed de-HEMO study timeline
scription of cardiovascular disease. This was especiallyIn response to results of observational and uncon-
important because hospitalization for new onset or wors-trolled studies conducted in the late 1980s, the National
ening of cardiovascular disease is a secondary outcomeInstitutes of Health issued a Request for Applications
for the HEMO Study. Two disease categories, hemato-to plan and conduct a randomized clinical trial that would
logical conditions and anticoagulant use, were added forassess the relationship between dialysis dose and mortal-
the full-scale study because there was no existing categoryity. A pilot study, the Mortality and Morbidity in Hemo-
to capture nonmalignant hematological conditions (fordialysis (MMHD) Study, was performed between 1993
example, sickle cell anemia) or the adverse effects ofto 1994 to assess the feasibility of attaining a higher-
anticoagulation. These modifications enhance the contentthan-usual target Kt/V, of maintaining a clear separation
validity of the instrument for use in a dialysis population.between usual and high Kt/V groups, and of testing pro-
A single ICED score, ranging from 0 to 3 with 3 ascedures to be used in the full-scale trial, including comor-
the highest severity level, was assigned to each patient.bidity assessment [15, 18]. Enrollment in the full-scale
The score was derived from two separate assessments:trial, the HEMO Study, began in March 1995 and is
the Index of Disease Severity (IDS) and the Index ofongoing. Baseline data from the pilot study and from
Physical Impairment (IPI; Table 1). The IDS was a medi-the first 1000 patients randomized in the full-scale trial
cal record-based assessment of 19 medical conditions,are reported here.
each defined by four severity levels. The IDS was scored
Definition of comorbidity by trained study personnel from data collected during
review of the medical records. To standardize the processComorbidity, as defined by Feinstein in 1970 [19, 20],
refers specifically to medical conditions other than the across multiple dialysis units, study personnel were in-
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Table 1. Description of the components of the Index of Coexistent Diseases (ICED)
Severity level Index of Disease Severity (IDS) Index of Physical Impairment (IPI)
0 None, condition absent No significant impairment, normal function
1 Little or no morbidity Mild/moderate impairment, symptomatic, may
need assistance with activities of daily living
2 Symptomatic, active, but controlled, requiring ongoing Serious/severe impairment, symptomatic
treatment
3 Moderate, severe manifestations despite treatment
Conditions or impairments Ischemic heart disease Circulation
Congestive heart failure Respiration
Arrhythmias Neurologic function
Other heart disease Mental function
Hypertension Urinary elimination
Cerebral vascular disease Bowel elimination
Peripheral vascular disease Feeding
Diabetes mellitus Ambulation
Respiratory disease Vision
Malignancy Hearing
Hepatobiliary disease Speech
Gastrointestinal disease
Neurological disease
Arthritis
Hematological disease
HIV/AIDS
Anticoagulation
structed to obtain the following medical records and records were compiled and reviewed by study personnel
in each clinical center (nurses or dietitians), after trainingalso to record whether each of these data sources was
available: the dialysis chart problem list, history and by a nurse (AAM) familiar with the process and NEMC
physicians (NVA, DCM, KBM, and ASL). Study person-physical examination, physician progress notes, hospital
discharge summaries, consultations, medication records, nel underwent a four-hour training session that focused
on data collection, scoring the ICED and computerizedchest x-ray reports, electrocardiograph reports, echocar-
diogram reports, and other information. data entry. If a reviewer encountered a problem in coding
a medical condition or rating its severity, the clinicalThe IPI was an observer-based assessment of 11 physi-
cal impairments, each defined by three severity levels. center principal investigator (physician) was consulted,
and if necessary, study personnel at NEMC were con-Dialysis unit personnel familiar with the patient’s func-
tional status scored the IPI with input from a family sulted. Study personnel attended annual refresher train-
ing sessions.member or caretaker as necessary. Table 1 lists the IDS
and IPI categories and summarizes the definitions of
Study subjectsseverity levels. The final ICED score was determined by
Patients were eligible for the HEMO Study if theycombining the single highest (“peak”) IDS score (range
were dialyzed three times per week for more than three0 to 3) with the peak IPI score (range 0 to 2) according
months. Patients were excluded if they were scheduledto the algorithm in Figure 1 (top part). There was no
for a living related renal transplant, had returned toincrement in the score for patients with more than one
dialysis less than six months after renal transplantation,IDS or IPI condition with the same peak score. The total
were unable to achieve an equilibrated Kt/V of 1.3 innumber of conditions and impairments did not factor
4.5 hours or less due to large body size or access prob-into the final ICED score.
lems, had residual renal urea clearance1.5 mL/min per
Implementation of the ICED in the pilot and 35 L volume of distribution for urea, or had any of the
full-scale studies following medical conditions: pregnancy, malignancy re-
quiring ongoing chemotherapy or radiation, unstable orIn both the pilot and full-scale study, comorbidity was
assessed during the baseline period, prior to randomiza- new onset ischemic heart disease within the past three
months, severe congestive heart failure (New York Hearttion. In the pilot study, dialysis unit records from all clin-
ical centers were compiled. Patient identifiers were re- Association Class IV) despite maximal medical therapy,
AIDS, an active systemic infection (for example, tuber-moved, and records were photocopied and sent to a
central facility [New England Medical Center (NEMC)]. culosis), chronic pulmonary disease requiring supple-
mental oxygen, severe liver disease (encephalopathy orA single reviewer (AAM), a former dialysis nurse, scored
all of the records. In the full-scale study, dialysis unit elevated prothrombin time), or severe malnutrition (se-
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Fig. 1. Algorithm for derivation of Index of Co-
existent Diseases (ICED) levels from Index of
Disease Severity (IDS) and Index of Physical
Impairment (IPI) scores. The proportion of pa-
tients within each severity level of the ICED
are displayed according to the IPI and IDS cate-
gory score that lead to the final ICED score.
rum albumin 2.6 g/dL). The study protocol was ap- system (for example, IDS categories of ischemic heart
disease or congestive heart failure and IPI categories ofproved by the Investigative Research Board at all institu-
tions, and written informed consent was obtained from circulatory or respiratory impairments) would be more
correlated than categories assessing different organ sys-all study participants.
tems (for example, IDS category hepatobiliary disease
Baseline assessments and IPI category of visual impairment). Associations
between the peak IPI and the KI and between the peakDemographic and socioeconomic information was col-
lected through self-reported questionnaires. Clinical data IPI and physical functioning (PF) scales of the SF-36
also assessed construct validity, since these other scalesincluding blood pressure, dietary intake, laboratory mea-
surements, and anthropometric measures were obtained measure observer-based or self-reported functional sta-
tus, and would be expected to decrease with increas-using standardized protocols [15]. These particular vari-
ables were chosen a priori based on the clinical expec- ing physical impairment [4, 8, 28, 30, 31]. Relationships
were assessed using Kendall-Taub correlations for cate-tation that they would be associated with comorbidity.
Additional data on functional status were collected using gorical variables.
The proportion of patients affected by each IDS andthe Karnofsky Activity Index (KI) and the Medical Out-
comes Study Short-Form 36 (SF-36) questionnaire. Briefly, IPI category was described across ICED levels. The dis-
tribution of baseline demographic, socioeconomic andthe KI is an observer-based assessment of impairment
of functional status due to illness [27, 28]. It includes ten clinical values across ICED levels was compared using
means (SD) and one-way analysis of variance (ANOVA)levels, with higher scores indicating higher functional
status. The SF-36 is a self-administered questionnaire that for continuous variables and frequency and chi-square
tests for categorical ordinal variables. ICED levels 0measures general health status in eight domains: physical
functioning, role-physical, bodily pain, general health and 1 were combined in all analyses because there were
only two patients with an ICED level of 0.perceptions, vitality, social functioning, role-emotional,
and mental health [29]. Each scale is graded from 0 to Associations between patient characteristics (cause of
renal disease, demographic, socioeconomic, and clinical100, with higher scores indicating higher quality of life.
parameters) and the ICED level were assessed using
Statistical analysis ordinal logistic regression, with ICED as an ordinal out-
come variable. The odds ratios indicate the ratio of theThe proportion of patients across the severity levels
(0 to 3) of the 19 disease (IDS) categories, and across odds of a one-unit increase in the ICED corresponding
to the stipulated change in the predictor variable, con-the severity levels (0 to 2) of the 11 physical impairment
(IPI) categories were described by frequency plots. trolling for the other variables in the model. Two multi-
variable ordinal logistic regression models were devel-As a measure of construct validity, we hypothesized
that IDS and IPI categories that targeted the same organ oped. The first model consisted of cause of renal disease,
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demographic and socioeconomic variables only. The sec- [33] between the single nurse reviewer and a physician
for the 49 patients.ond model also included clinical parameters (blood pres-
sure, dietary intake, anthropometry, and laboratory data).
Full-scale study: Baseline characteristics of theWe reasoned that abnormalities in these clinical parame-
first 1000 randomized patientsters develop as a result of comorbid illness and the associ-
ations of the cause of renal disease. Therefore, the rela- At the time of this analysis, 1404 patients had entered
the baseline period, and 404 were excluded for one ortionships of cause of renal disease, demographic and
socioeconomic variables with ICED were analyzed with more of the following reasons: excess residual renal func-
tion (N 152, 37.6%), patient or study team preferencesand without clinical parameters to ensure that they did
not cause colinearity. The models were constructed as (N  169, 41.8%), inability to meet the minimal target
Kt/V (N  12, 3.0%), medical conditions (N  50,follows. Relationships between each variable and the
ICED were tested in univariate analyses. Variables sig- 12.4%), incomplete baseline forms (N  18, 4.5%), or
the reason for exclusion was missing (N  4, 0.7%).nificant (P  0.10) in univariate analyses were entered
one at a time in the multivariable model, and retained The mean age of the study group was 58 years; 53.6%
were females, while 64.7% were black, and 36.4% hadif the adjusted relationship was significant at a P value
of 0.05. Clinical center was added as a fixed covariate diabetes as the cause of ESRD. The mean duration of
dialysis prior to enrollment into the study was 4.26 years.to the final multivariable model that included all other
significant covariates. The amount of variability in the Mean equilibrated Kt/V was 1.30. Hematocrit was 32.6%.
Serum creatinine was 10.7 mg/dL, and serum albuminICED score explained by the covariates in the final
model was assessed using an adjusted coefficient of deter- was 3.7 g/dL.
mination (adjusted R 2) appropriate for ordinal logistic
Comorbidity in the full-scale studyregression [32].
The frequency with which data sources were available
Inter-rater reliability for comorbidity assessment is displayed as the mean and
range across clinical centers in Table 2. The problemIn the pilot study, each patient’s dialysis chart was re-
viewed independently by a single physician (NVA) and list, history and physical examination, hospital discharge
summary, physician progress notes, medication record,a nurse (AAM) and the assigned IDS scores were com-
pared. Inter-rater reliability was assessed using the kappa chest x-ray, and electrocardiograph report were available
in more than 75% of patients. Consultant reports, echo-statistic. In the full-scale study, six charts from the pilot
study were assessed independently by 24 reviewers from cardiogram reports, and other sources of data were avail-
able less often. There was substantial variability acrossthe 15 clinical centers, and IDS scores were compared
with those assigned by a single physician (ASL). All clinical centers for many of these data sources.
Distributions of the IDS and IPI scores are shown inreviewers were given the same sources of data to com-
plete the scoring. Inter-rater agreement across the 19 Figures 2 and 3. There is a striking burden of comorbid-
ity; 99.8% of patients were observed to have at least 1IDS categories between the nurse reviewers and physi-
cian was assessed as the average percent agreement of the 19 disease conditions from the IDS. One third to
one half of the patients had IDS scores of two to three,across categories. The proportion of reviews that agreed
with the physician for the final peak IDS score also was indicating symptomatic disease, the need for medica-
tions, or hospitalizations. The most prevalent disease wasreported. Inter-rater reliability in IPI was not assessed
because it was logistically difficult to arrange to have hypertension, present in more than 90% of patients, with
the majority scored as IDS level two, indicating the needmultiple assessments of the same patient. The time for
completion of each chart is described as a mean and for medications. Cardiovascular disease was very com-
mon, with 81% of patients having at least one or morestandard deviation.
of the four cardiac categories: 41% had ischemic heart
disease. Thirty-eight percent had congestive heart fail-
RESULTS
ure. Thirty-three percent had arrhythmias, and 66% had
Pilot study other heart diseases. Cerebrovascular disease was re-
corded for 19% of patients, of whom 70% were affectedComorbidity information was successfully collected
and summarized using the ICED in the pilot study. A with multiple transient ischemic attacks, were currently
anticoagulated for prevention of ischemic events, or hadtotal of 49 patients were enrolled. The percent of patients
distributed among the four ICED levels from 0 to 3 a prior stroke with residual neurological deficit. Periph-
eral vascular disease was reported in 24% of patients;was 0, 51, 12, and 37%, respectively. These results were
similar to results observed by others in dialysis patients approximately one third of these individuals had severe
disease, defined as pain at rest, inoperable disease, or a[11, 17]. The resultant inter-rater agreement in IDS scor-
ing was   0.72, which suggests substantial agreement history of a below- or above-knee amputation. Gastro-
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Table 2. Availability of data sources for comorbidity assessment
Available for review across clinical centers
Item Mean % Minimum % Maximum %
Problem list 80 26 100
History and physical examination 88 55 100
Hospital discharge summary (most recent) 81 30 100
Physician progress notes (over the past 12 months) 86 6 100
Consultant reports 51 8 99
Medication record (most recent) 99 98 100
Chest x-ray report (most recent) 79 52 100
Electrocardiograph report 87 55 100
Echocardiogram report (most recent) 40 13 100
Reports of other studies 53 1 97
Other knowledge of the patient’s condition 37 0 95
Other information 17 0 93
Fig. 2. Distribution of IDS categories and se-
verity levels. Categories are: 1, ischemic heart;
2, congestive heart failure; 3, arrhythmia; 4,
other heart disease; 5, hypertension; 6, cereb-
rovascular disease; 7, peripheral vascular dis-
ease; 8, diabetes mellitus; 9, respiratory; 10,
musculoskeletal; 11, nonvascular nervous sys-
tem; 12, gastrointestinal disease; 13, hepatobil-
iary disease; 14, urinary tract; 15, malignancy;
16, HIV/AIDS; 17, ophthalmological; 18, he-
matological; and 19, anticoagulation. The re-
maining proportions out of 100 are the patients
without disease in that particular category
(level 0). Symbols are for the peak IDS score:
( ) severe; ( ) moderate; ( ) mild.
intestinal conditions were observed in 35% of patients, difficulties sufficient to impair activities of daily living
were reported in 19% of patients, and 7% of patientsthe majority of whom were affected by gastroesophageal
reflux or peptic ulcer disease. Eight percent of patients were legally blind. Substantial difficulties with hearing
despite hearing aids were present in 8% of patients.were chronically infected with hepatitis B or C, and 18%
of these patients had elevated enzymes or were treated Another 8% had difficulties with feeding or swallowing,
and 6% had difficulties with speech, communicated withwith medications for liver disease. Only 9% of patients
had a history of malignancy, and only 11% of these sign language, or were aphasic.
Figure 1 (bottom part) shows the distribution of pa-patients had disease diagnosed within the past year.
Approximately two thirds of the study group were ob- tients’ combined scores and ICED levels. Overall, the
proportion of the patients having ICED levels from zeroserved to have one or more physical impairments. Circu-
latory or respiratory impairments were reported in 20 to three was 0.2, 34.9, 31.2, and 33.7%, respectively. The
mean (SD) ICED score was 1.98 (0.83).to 25% of patients, with the majority (98%) having mild
disease, defined as dyspnea, chest pain or claudication The mean (SD) Karnofsky Activity Index was 79.6
(16.8). The distribution and interpretation of scores werewith walking. A strikingly high proportion of patients,
31%, were noted to have an impaired ambulation. Of as follows: no patients had a score below 39 (requiring
institutionalization); 21% had scores between 40 andthese, 67% had mild impairment, defined as the need to
walk with assistance, a cane or the transient use of a 69 (requiring a caretaker). Eleven percent had scores
between 70 and 79, (self-care only), and the remainingwheelchair, and the remaining 33% were confined to a
wheelchair or were reported as being bedridden. Visual 68% scored between 80 and 100 (full rehabilitation).
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Fig. 3. Distribution of IPI categories and se-
verity levels. Physical impairment in the follow-
ing organ systems: 1, circulatory; 2, respiratory;
3, neurological; 4, mental status; 5, urogenital;
6, fecal; 7, feeding; 8, ambulation; 9, vision;
10, hearing; 11, speech. The remaining propor-
tions out of 100 are patients without disability
in that particular category (level 0). Symbols
are for the peak IPI score: ( ) severe; ( )
mild to moderate.
These results are similar to the results from two large or impairments per patient. The percent of patients af-
fected by each IDS and IPI category are reported acrossstudies of prevalent hemodialysis patients. In one study
of 107 patients two years after the start of dialysis, the ICED levels (Table 3). Overall, we observed an increas-
ing prevalence of most categories of the IDS and IPI atmean KI score was 65.6 [34]. In another second study
of 149 patients, the mean (SD) score was 76.6 (18) [28]. higher ICED levels. In addition, the numbers of IDS
and IPI categories per patient were significantly higher
Construct validity (relationship between the IPI and at higher ICED levels (P  0.001 for both).
IDS and between the IPI and other measures of
physical function) Factors associated with comorbidity
The distribution of demographic, socioeconomic, andCorrelations between pairs of IDS and IPI categories
targeting the same organ system were higher (15 pairs, clinical characteristics across ICED levels is shown in
Tables 4 and 5. Patients with higher ICED levels weremedian r  0.19, interquartile range r  0.06 to 0.25)
than the correlation between pairs in different organ older, had been on dialysis for a shorter period of time,
and more often had diabetes as the cause of renal disease.systems (9 pairs, median r  0.006, interquartile range
r  0.02 to 0.06). Correlations between the peak IPI Race and gender distributions were not significantly dif-
ferent among ICED levels. Comorbidity was higher inwith measures of physical function [KI and the SF-36
physical functioning (PF) score] were higher than the married versus unmarried patients, unemployed versus
employed patients and in those who had less than a highcorrelation between peak IPI and the SF-36 mental
health (MH) score (r  0.56 and 0.27 vs. r  0.07, school level of education. Patients with higher comorbid-
ity scores had significantly lower albumin, serum creati-respectively). Similarly, correlations of the ICED were
stronger with the KI, and SF-36 PF score than SF-36 nine and BMI as compared with patients with less severe
comorbidity.MH score (r  0.53 and r  0.27 vs. r  0.08,
respectively). These results are consistent with the usual Results of multivariable ordinal logistic regression
models are in Table 6. In the model including only theprofiles of SF-36 scores, whereby increasing illness sever-
ity correlates with physical functioning but not mental cause of renal disease, demographic and socioeconomic
factors, the odds of a one-level increase in the ICEDhealth [30].
was significantly (P value 0.05) associated with older
Distribution of IDS and IPI categories across age, Caucasian race, diabetes and “other” causes of renal
ICED levels disease, a lower level of education, unemployment (ver-
sus working), and a longer interval since beginning dial-The ICED score is defined by the peak severity of the
IDS and IPI categories, not by the number of conditions ysis. After adjustment for clinical variables, race was no
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Table 3. Distribution of comorbid conditions across Index of Coexistent Diseases (ICED) levels
ICED 0–1 ICED 2 ICED 3
(N351) (N312) (N337)
Medical conditions (IDS categories)
Ischemic heart disease % 26.5 42.3 54.3
Congestive heart failure % 25.9 42.3 47.8
Arrhythmia % 25.6 30.8 41.5
Other heart disease % 54.4 73.4 72.1
Hypertension % 94.3 95.5 95.8
Cerebrovascular % 8.3 19.6 30.9
Peripheral vascular % 10.5 22.1 40.7
Diabetes mellitus % 24.5 44.2 58.2
Respiratory % 8.5 16.7 19
Musculoskeletal % 43.9 47.1 46.3
Neurological % 21.4 38.8 48.7
Gastrointestinal % 24.2 37.8 45.1
Hepatobiliary % 14.2 12.2 23.7
Urogenital disease % 6.6 8.3 5.6
Malignancy % 7.1 8.3 11.0
HIV % 0.9 0 0
Ophthalmological % 12.3 26.3 42.7
Hematological disease % 4.6 4.5 3.9
Anticoagulation % 9.1 8.7 11.0
Mean (SD) number 4.2 (2.2) 5.8 (2.3) 7.0 (2.4)
Impairments (IPI categories)
Circulation % 0 33.7 41.2
Respiratory % 0 32.7 29.4
Neurological % 0 36.5 40.9
Mental % 0 20.5 31.8
Urinary % 0 8.0 14.0
Fecal % 0 14.4 15.4
Feeding % 0 3.2 8.9
Ambulation % 0 39.1 56.7
Vision % 0 26.3 37.1
Hearing % 0 6.1 9.5
Speech % 0 1.6 7.1
Mean (SD) number 0 2.2 (1.4) 2.9 (2.3)
Abbreviations are: IDS, Index of Disease Severity; IPI, Index of Physical Impairment. Percent of patients with IDS or IPI severity 0. By definition, patients in
ICED level 0–1 have IPI severity  0.
longer significant, but the other factors remained signifi- DISCUSSION
cant, as was a lower serum creatinine. The ICED is a standardized method of assessing co-
Distributions of IDS, IPI, and ICED levels varied sig- morbidity that has been shown to be a valid predictor
nificantly among clinical centers (data not shown). Varia- of mortality in prior studies of dialysis patients (abstract;
tion in ICED levels among clinical centers remained Miskulin, J Am Soc Nephrol 10:175A, 1999) [11, 17].
significant after controlling for all other factors in the To our knowledge, this report is the largest published
multivariable analysis. Altogether, the variables included experience in which a comprehensive and detailed as-
in the multivariable model accounted for 25.3% (ad- sessment of the presence and extent of comorbidity has
justed R 2) of the variability in the ICED. been undertaken in a national hemodialysis population.
The HEMO Study sample differs in some important
Inter-rater agreement in the full-scale study ways from the prevalent U.S. hemodialysis population
Overall, there was good agreement between reviewers [35]. The HEMO Study includes a higher proportion of
at the clinical centers. The agreement between the nurse African Americans (64.7 vs. 32.1%), which likely reflects
reviewers and the physician across individual IDS cate- the geographic distribution of the 15 clinical centers.
gories averaged 84.3%. The proportion of reviews that The HEMO Study also includes a higher proportion of
were in agreement with the physician-assigned peak IDS women (53.6 vs.45.7%), probably reflecting lower body
score was 82.6%. The time to review the medical record mass index and the ability to meet the entry requirement
and complete the IDS averaged 51 minutes (SD 12) per of a delivered equilibrated Kt/V 1.3 in less than 4.5
chart. There was no correlation between the completion hours. However, neither race nor gender had a significant
time and the percent disagreement in IDS categories at independent association with comorbidity in the multi-
variable regression models. Thus, these differences prob-each center.
Miskulin et al: Comorbidity assessment in the HEMO Study1506
Table 4. Baseline demographic and socioeconomic characteristics and causes of renal disease
All ICED 0–1 ICED 2 ICED 3
Baseline characteristics (N1000) (N351) (N312) (N337) P value
Age years 58 (14) 53.2 (14.5) 60.1 (13.0) 60.0 (12.5) 0.001
Female % 53.6 48.7 57.1 55.5 0.70
Race % 0.17
Caucasian 32.1 28.1 33.2 35.3
African American 64.7 68.5 62.6 62.6
Other 3.2 3.4 4.2 2.1
Cause of renal disease % 0.001
Glomerular diseases 15.8 21.8 16.5 8.8
Diabetes 36.4 19.8 37.3 52.7
Hypertension 32.6 39.8 33.7 24.1
PKD 3.3 5.3 2.6 1.8
Other 12.0 13.3 9.9 12.5
Interval since starting dialysis years 4.3 (4.5) 4.6 (5.1) 4.4 (4.5) 3.8 (3.8) 0.08
Education %
high school (12 years) 59.2 67.5 53.8 55.4 0.001
Marital status % 0.001
Single 18.6 26.2 15.4 13.7
Married 40.3 39.6 40.4 41.1
Divorced/separated/widowed 41.1 34.2 44.2 45.2
Employment status % 0.001
Working 12.2 20.0 8.7 7.4
Not working/unknown 57.9 59.5 55.8 58.2
Retired 29.9 20.5 35.6 34.4
Income % 0.70
$25,000 50.5 48.2 52.9 50.7
$25,000 16.1 16.2 16.7 15.4
Refused, unknown 33.4 35.6 30.4 33.8
Insurance other than Medicare or Medicaid only % 49.4 49 50 49 0.98
Abbreviations are: ICED, Index of Coexistent Diseases; PKD, polycystic kidney disease. The sample size used in the description of variables ranged from 970–1000
patients. Data are presented as percent or mean (SD). The frequency across ICED levels was tested for statistical significance using chi-square tests for categorical
variables and one-way ANOVA for continuous variables.
Table 5. Baseline clinical characteristics across Index of Coexistent Diseases (ICED) levels
All ICED 0–1 ICED 2 ICED 3
Baseline characteristics (N1000) (N351) (N312) (N337) P value
Hematocrit % 32.6 (4.3) 32.5 (4.2) 32.6 (4.2) 32.6 (4.4) 0.93
Equilibrated Kt/V 1.30 (0.22) 1.30 (0.22) 1.31 (0.22) 1.30 (0.21) 0.67
Creatinine mg/dL 10.7 (2.9) 11.8 (3.2) 10.4 (2.7) 9.7 (2.6) 0.001
Phosphorous mg/dL 5.8 (1.9) 5.9 (1.8) 5.8 (1.9) 5.6 (1.9) 0.26
Albumin g/dL 3.7 (0.4) 3.8 (0.4) 3.7 (0.4) 3.6 (0.4) 0.001
Interdialytic weight gain kg 2.8 (1.2) 2.8 (1.2) 2.9 (1.2) 2.8 (1.3) 0.84
Pre-dialysis SBP mm Hg 152 (25) 149 (25) 152 (24) 155 (27) 0.03
BMI kg/m2 25.3 (5.2) 24.8 (4.6) 26.2 (5.7) 24.9 (5.1) 0.001
nPCR g/kg/day 0.99 (0.25) 1.02 (0.25) 0.98 (0.23) 0.98 (0.26) 0.04
Protein intake g/kg/day 0.93 (0.36) 0.97 (0.38) 0.91 (0.34) 0.91 (0.35) 0.03
Energy intake 10 kcal/kg/day 22.9 (8.4) 23.7 (8.4) 22.6 (8.2) 22.2 (8.4) 0.05
Results are reported as the mean value and standard deviation across ICED levels. Statistical significance between ICED levels was tested using ANOVA. The
sample size used in the description of variables ranged from 973–1000 patients.
Abbreviations are: SBP, systolic blood pressure; BMI, body mass index; nPCR, protein catabolic rate normalized to standard body weight. Definitions: All were
measured during the 6-week baseline period prior to enrollment to the study. nPCR was assessed by urea kinetic modeling. Protein and energy intakes were assessed
by 24-hour assisted dietary recall.
ably do not affect the generalizability of the description among prevalent U.S. hemodialysis patients is probably
at least as severe as in the HEMO Study.of comorbidity in the HEMO Study. Also, the HEMO
Study excludes patients with residual renal function, un- This study indicates that comorbid conditions are very
common in prevalent hemodialysis patients; 99% of pa-stable angina, severe cardiac, pulmonary, or liver disease,
AIDS and systemic infections, malignancies requiring tients had one or more medical conditions, while 61%
had one or more physical limitation. While it is well-chemotherapy or radiation, and hospitalized patients. It
can be concluded then that the burden of comorbidity known that dialysis patients have many comorbid condi-
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Table 6. Relationships between cause of renal disease, demographic, socioeconomic and clinical variables and Index of Coexistent Diseases
(ICED) level in multivariable logistic regression models
Multivariable model, including Multivariable model, including
cause of renal disease, demographic cause of renal disease, demographic,
and socioeconomic factors socioeconomic and clinical factors
Factor (unit) Odds ratio 95% CI Odds ratio 95% CI
Age 10 years 1.33 1.18–1.50 1.27 1.12–1.46
Race
Caucasian (ref) 1.00 1.00
African American 0.68 0.50–0.94 0.80 0.57–1.11
Other 0.60 0.27–1.34 0.62 0.27–1.40
Cause of renal disease
Glomerular diseases (ref) 1.00 1.00
Diabetes 4.08 2.73–6.15 3.62 2.36–5.59
Hypertension 1.36 0.91–2.04 1.40 0.92–2.13
PKD 0.71 0.32–1.53 0.75 0.33–1.63
Other 1.94 1.19–3.15 1.73 1.04–2.86
Education
Grade 12 (ref) 1.00 1.00
Grade 12 0.66 0.51–0.87 0.66 0.50–0.87
Duration dialysis 1 year 1.03 1.00–1.06 1.04 1.01–1.07
Employment
Working (ref) 1.00 1.00
Not working 2.05 1.35–3.14 1.93 1.25–2.99
Retired 1.77 1.09–2.91 1.63 0.99–2.70
Creatinine 1.0 mg/dL 0.90 0.85–0.95
Abbreviations are: GN, glomerulonephritis; PKD, polycystic kidney disease; (ref), referent category. Definitions are for two multivariable models are shown. The
multivariable model on the left shows the relationship of cause of renal disease, demographic and socioeconomic factors to the ICED level. The multivariable model
on the right includes the same factors as well as clinical factors (blood pressure, dietary intake, anthropometry and laboratory values). Both models are adjusted for
clinical center.
Interpretation: The odds of a one-level increase in ICED score for a patient with renal failure due to diabetes is 3.62 times greater than a patient with GN as the
cause of renal disease, after controlling for all other factors.
tions [6, 7, 14, 35–37], physical impairments within organ peak IPI categories, a strong relationship between indi-
vidual disease categories and impairments is less impor-systems have not been characterized previously in a large
dialysis population, nor considered as an additional di- tant than capturing the severity of disease within one or
more categories of both scales.mension of the comorbidity assessment. In addition, the
ICED includes explicit definitions for severity in both the Including information on physical impairments in the
assessment of comorbidity is a distinct advantage of theIPI and IDS and thereby provides a more comprehensive
summary of the presence and extent of comorbidity than ICED. Physical impairments are considered an addi-
tional dimension of comorbidity [40] that reflect symp-other methods.
The stronger correlations between related versus un- tomatic, uncontrolled, or advanced stages of disease. Past
studies in dialysis patients have shown a strong relation-related IDS and IPI categories demonstrate construct
validity. However, the correlations between related cate- ship of reduced physical functioning as assessed by KI
and SF-36 physical functioning with mortality [8, 41].gories were relatively weak. There are several possible
explanations for this. First, there are a limited number There are important differences among the ICED, KI,
and SF-36. The ICED captures physical symptoms andof levels for each IDS and IPI category. Second, the IDS
is based on information from the medical record, while limitations reflecting the stage of disease in various organ
systems, from which prognosis can be estimated. Thethe IPI is observer based. Other studies have shown that
chronic conditions that do not require ongoing physician KI and SF-36 physical functioning scale predominantly
focus on motor disability and its effects on the patient’sassessment are frequently underreported in the medical
record [38, 39]. Third, the IDS and IPI are probably day-to-day functioning and perceived quality of life. As
expected, the ICED correlations were significant butcapturing different information. A specific physical im-
pairment can be the result of several different diseases. weak, which suggests the ICED does not simply replicate
information collected by these other instruments. Al-For example, impairment in ambulation may reflect isch-
emic heart disease, congestive heart failure, peripheral though all are correlated with a poor prognosis, we hy-
pothesize that the ICED is likely to perform better invascular disease, or neuropathy. Similarly, impairment
in circulation and respiration may reflect ischemic heart predicting risk of future events, as it contains subjective
and objective clinical information that is combined spe-disease, congestive heart failure or respiratory disease.
Because the ICED level is based on the peak IDS and cifically to gauge disease severity.
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The prevalence of diseases and impairments increased clinical centers is likely due to differences in the case-
mix of the patients. This emphasizes the importance ofwith overall comorbidity severity in the HEMO Study, as
did the number of diseases and impairments per patient. adjusting for baseline comorbidity when analyzing out-
comes in multicenter studies.Thus, although the ICED score is based on the severity
rather than the number of comorbid diseases or impair- In observational studies and uncontrolled clinical tri-
als, adjustment for comorbidity is necessary to avoidments, a higher ICED level reflects a greater number of
comorbid conditions. From a clinical perspective, this is confounding by imbalances across clinical centers. In
large randomized clinical trials, in which randomizationan expected finding because the cause of renal failure
may be a systemic disease that continues to progress in is stratified by clinical center, it is expected that comor-
bidity as well as most other baseline characteristics willother organs after dialysis is started and because renal
failure leads to complications in multiple organs. be balanced across randomized groups. Therefore, ad-
justment for baseline comorbidity should not be neces-The most significant factors associated with more se-
vere comorbidity in the HEMO Study included older sary to control for imbalances between randomized
groups. However, if a baseline factor is strongly associ-age, a longer interval since beginning dialysis, diabetes
and other causes of ESRD, an education of less than ated with the outcome, then adjustment for the baseline
factor should increase the precision of assessing the effectgrade 12 level, employment status (unemployed vs.
working), and lower serum creatinine. Numerous studies of treatment on the outcome. In the HEMO Study, the
primary analysis will be a comparison of randomizedshow increasing number of comorbid conditions in older
and diabetic patients undergoing dialysis [7, 14, 35, 36, groups (high vs. usual Kt/V and high vs. low flux), con-
trolling for a variety of baseline factors, including comor-42, 43]. The relationship between lower socioeconomic
status, as reflected by educational level and employment, bid conditions. This is a useful strategy to increase statis-
tical power, given a fixed sample size [15, 16].with higher morbidity has been a consistent finding in
other studies [37]. This may reflect poor dietary habits, The ICED is intended to provide a comprehensive
summary of comorbidity and its prognostic significance,substance abuse, inability to afford medical care or time
off work for medical assessments, inattention to preven- to be used for case-mix adjustment purposes. We recog-
nize that there are some limitations of the instrument.tive measures, or recognition of earlier treatable stages of
disease. Decreased serum creatinine also was associated First, the four-level scale does not reveal the wealth of
information that is captured by the ICED. However, wewith higher comorbidity and likely reflected small muscle
mass and/or malnutrition, which have been shown to be argue that it is not practical to describe the detail of
comorbidity information collected using the ICED forassociated with comorbidity [3, 42, 44, 45]. A large
amount of the variability in the ICED score was unac- each individual patient, whether for research or quality
assessment studies, and thus a summary measure is es-counted for in the multivariable model, which suggests
that the extent and severity of comorbid conditions can- sential. However, an additive scale with a greater number
of levels could take into account the number of condi-not be measured accurately simply by assessing the cause
of renal disease, demographic, socioeconomic, and clini- tions per patients and may provide improved discrimina-
tion in predicting risk for future events. The detail ofcal variables.
We found significant variation in ICED scores among comorbidity and outcomes data collected during the
HEMO Study will enable us to explore alternate meth-clinical centers that persisted after adjustment for differ-
ences in cause of renal disease, demographic, socioeco- ods to re-scale the instrument and the effects of addi-
tional summary levels.nomic, and clinical factors. In principle, variability in
ICED levels across clinical centers could represent error In addition, there are some limitations of the analyses
reported. The temporal relationships of the cause of renalin instrument scoring or true differences in case-mix se-
verity among centers that were not measured and ac- disease, demographic, socioeconomic, and clinical vari-
ables with comorbidity cannot be determined, due to thecounted for in the multivariable model. The inter-rater
agreement in IDS scoring was high (83%), and when cross-sectional nature of the data. Analysis of follow-up
data from the HEMO Study will allow us to relate thethis term was added to the multivariable model, it did
not lessen the effect of center on ICED variation. How- ICED level at baseline, as well as the individual IDS or
IPI categories, to clinical outcomes, such as death orever, we found that other measures of case-mix severity
(for example, mean age, the proportion of patients with hospitalizations. In other studies, comorbidity is itself a
strong predictor of death, as are the cause of renal diseasediabetes, KI scores, and SF-36 scores) paralleled differ-
ences in ICED scores across clinical centers (data not and the demographic, socioeconomic, and clinical factors
that were associated with higher ICED scores in theshown). It is difficult to determine how much of the
variability in ICED across clinical centers is due to varia- HEMO Study [3, 6, 7, 11, 13, 14, 17, 37, 42, 46]. Finally,
comorbidity is being assessed annually in the HEMOtions in reliability of scoring versus true differences in
case-mix, but these results suggest that variability across Study, which will enable a detailed description of changes
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